Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Treatment and prevention of cardiovascular disease

The potential of next generation omega-3 fatty acids

Impact of the Pandemic on Medical and Scientific Affairs

Dr. Shurjeel Choudhri, SVP and Head, Medical and Scientific Affairs at Bayer Canada, dives into a range of hot topics, from innovative digital technologies and beyond-the-pill medicine to the concept of patient-centricity....

Impetus Digital

- PMLiVE

Perfect partners

What are the key components for a successful partnership and how can that be achieved?

Roche Basel Switzerland

Roche gets EU approval for fixed-dose Herceptin/Perjeta combination

Treatment can be administered as an injection instead of an intravenous infusion

- PMLiVE

Abivax’s COVID-19 study declared Research National Priority by French government

Drug treatment is being investigated in high-risk COVID-19 patients

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

This is a new option for advanced prostate cancer patients in the US

- PMLiVE

GSK signs collaboration deal with Ligand targeting neurological disorders

This is the latest in a string of pipeline deals announced by GSK

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Dear Joe

An open letter to the incoming President of the United States on COVID-19 messaging priorities

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links